Article Information
History
- September 7, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Preethi Eldi1,*,
- Tamara H. Cooper1,5,
- Natalie A. Prow1,5,
- Liang Liu1,4,
- Gary K. Heinemann1,
- Voueleng J. Zhang1,
- Abigail D. Trinidad1,
- Ruth Marian Guzman-Genuino2,
- Peter Wulff2,
- Leanne M. Hobbs1,2,
- Kerrilyn R. Diener1,3 and
- John D. Hayball1,2,*
- 1Experimental Therapeutics Laboratory, Clinical and Health Science Unit, University of South Australia, Adelaide, SA, 5000, Australia
- 2Sementis Limited, Hackney, SA, 5069, Australia
- 3Robinson Research Institute and Adelaide Medical School, The University of Adelaide, Adelaide, SA, 5005, Australia
- 4Gene Technologies Group, Department of Molecular Biology, Research, CSL Limited, Parkville, VIC, 3010, Australia
- ↵*Corresponding authors: Dr Preethi Eldi; Clinical and Health Sciences Unit, University of South Australia, GPO Box 2471, Adelaide, SA, 5001, Australia. Email: preethi.eldi{at}unisa.edu.au; Prof John Hayball; Sementis Limited, 25 North Tce, Hackney, SA, 5069, Australia. Email: john.hayball{at}unisa.edu.au
↵5 These authors contributed equally to this work.
Posted September 07, 2021.
The vaccinia-based Sementis Copenhagen Vector COVID-19 vaccine induces broad and durable cellular and humoral immune responses
